Tissue Regenix Appoints Orthopedic Clinical Advisory Board in the US

Tissue Regenix Group (AIM:TRX) ("Tissue Regenix” or "The Group”) the regenerative medical devices company announces the appointment of an orthopedic clinical advisory board for the US as the Group continues to gain momentum within this key orthopedic market.

The clinical advisory board consists of 5 experts across varying orthopedic specialities, with special emphasis in ligament reconstruction, meniscal replacement, and cartilage restoration. Included on this Board are:

• Steven Arnoczky, DVM—Director, Laboratory for Comparative Orthopedic Research, at Michigan State University, East Lansing, Michigan
• David Caborn, MD—Clinical Professor, Orthopedic Surgery at University of Louisville, Louisville, Kentucky
• Thomas Carter, MD—Team Physician for the NBA Phoenix Suns; member of The Orthopedic Clinic Association, Phoenix, Arizona
• Philip Davidson, MD—founder of Davidson Orthopedics in Salt Lake City, Utah
• Jack Farr II, MD— Knee restoration and Cartilage specialist at OrthoIndy in Indianapolis, Indiana

Tissue Regenix will work closely with this Board of esteemed individuals as it looks to commercialize its orthopedic products throughout the US. With the US sports medicine market valued at $3B, the appointment of this Board signifies the first major step towards a commercialization pathway in the US for the Group, with an initial focus on allograft (human tissue) applications.

While the initial focus will be to introduce allograft tissues treated with the proprietary dCELL^® process, allowing them to be stored at room temperature, Tissue Regenix will look to address unmet clinical needs for ligament reconstruction and meniscal replacement through their portfolio of OrthoPure™ products. OrthoPure™ XM (meniscus) and XT (tendon), both porcine tissue based devices, are currently undergoing clinical trials in the EU for CE Mark approval.

Drew Distin, VP Tissue Regenix Orthopedics, Inc. commented "We are very excited to assemble an advisory board of some of the top minds in the sports medicine arena. These professionals are renowned in the industry not only for their clinical expertise, but also for their pioneering research into the use of tissue engineering for ligament reconstruction, meniscal replacement and cartilage regeneration. We look forward to working closely with this team, utilizing their expertise to help guide our launch into the US orthopedic market.”

Tissue Regenix will also exhibit at its first major orthopedic convention this month, attending The American Orthopedic Society for Sports Medicine Annual Meeting in Colorado Springs, July 7^th-10^th with a booth positioned at #321.

About Tissue Regenix

Tissue Regenix is a leading medical devices company in the field of regenerative medicine. The company's patented decellularisation ('dCELL^®') technology removes DNA and other cellular material from animal and human tissue leaving an acellular tissue scaffold which is not rejected by the patient's body which can then be used to repair diseased or worn out body parts. The potential applications of this process are diverse and address many critical clinical needs such as vascular disease, heart valve replacement and knee repair.

Tissue Regenix was formed in 2006 when it was spun-out from the University of Leeds. The company commercialises academic research conducted by our partners around the World.

In November 2012 Tissue Regenix Group plc set up a subsidiary company in the United States - 'Tissue Regenix Wound Care Inc.', as part of its commercialisation strategy for its dCELL^® technology platform.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160705005653/en/